BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33849649)

  • 1. Validation of
    Jónsdóttir B; Ripoll MA; Bergman A; Silins I; Poromaa IS; Ahlström H; Stålberg K
    Cancer Imaging; 2021 Apr; 21(1):34. PubMed ID: 33849649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Mikkelsen MS; Petersen LK; Blaakaer J; Marinovskij E; Rosenkilde M; Andersen G; Bouchelouche K; Iversen LH
    Eur J Surg Oncol; 2021 Aug; 47(8):2134-2141. PubMed ID: 33812768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
    Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases.
    Dresen RC; De Vuysere S; De Keyzer F; Van Cutsem E; Prenen H; Vanslembrouck R; De Hertogh G; Wolthuis A; D'Hoore A; Vandecaveye V
    Cancer Imaging; 2019 Jan; 19(1):1. PubMed ID: 30616608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
    Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V
    Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [¹⁸F]FDG-PET/CT.
    Funicelli L; Travaini LL; Landoni F; Trifirò G; Bonello L; Bellomi M
    Abdom Imaging; 2010 Dec; 35(6):701-7. PubMed ID: 19784697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/MRI for the preoperative diagnosis and staging of peritoneal carcinomatosis: a prospective multireader pilot study.
    Vietti Violi N; Gavane S; Argiriadi P; Law A; Heiba S; Bekhor EY; Babb JS; Ghesani M; Labow DM; Taouli B
    Abdom Radiol (NY); 2023 Dec; 48(12):3634-3642. PubMed ID: 36308554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: Diagnostic performance in correlation with surgical findings.
    Garcia Prado J; González Hernando C; Varillas Delgado D; Saiz Martínez R; Bhosale P; Blazquez Sanchez J; Chiva L
    Eur J Radiol; 2019 Dec; 121():108696. PubMed ID: 31683251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT.
    Schmidt S; Meuli RA; Achtari C; Prior JO
    Clin Nucl Med; 2015 May; 40(5):371-7. PubMed ID: 25783507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body MRI with diffusion-weighted imaging as an adjunct to
    Willemse JRJ; Lahaye MJ; Kok NFM; Grotenhuis BA; Aalbers AGJ; Beets GL; Rijsemus C; Maas M; van Golen LW; Beets-Tan RGH; Lambregts DMJ
    Colorectal Dis; 2024 Feb; 26(2):290-299. PubMed ID: 38145899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients.
    Engbersen MP; Van' T Sant I; Lok C; Lambregts DMJ; Sonke GS; Beets-Tan RGH; van Driel WJ; Lahaye MJ
    Eur J Radiol; 2019 May; 114():146-151. PubMed ID: 31005166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A multicentre study of the FRANCOGYN research group.
    Delvallée J; Rossard L; Bendifallah S; Touboul C; Collinet P; Bricou A; Huchon C; Lavoue V; Body G; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2020 Nov; 49(9):101867. PubMed ID: 32663654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging roles of functional imaging in ovarian cancer with peritoneal carcinomatosis.
    An H; Lee EYP; Chiu K; Chang C
    Clin Radiol; 2018 Jul; 73(7):597-609. PubMed ID: 29685803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Pfannenberg C; Königsrainer I; Aschoff P; Oksüz MO; Zieker D; Beckert S; Symons S; Nieselt K; Glatzle J; Weyhern CV; Brücher BL; Claussen CD; Königsrainer A
    Ann Surg Oncol; 2009 May; 16(5):1295-303. PubMed ID: 19252950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET/CT.
    Kim HW; Won KS; Zeon SK; Ahn BC; Gayed IW
    Clin Nucl Med; 2013 Feb; 38(2):93-7. PubMed ID: 23334121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging of Peritoneal Carcinomatosis in Ovarian Carcinoma.
    Lee EYP; An H; Tse KY; Khong PL
    AJR Am J Roentgenol; 2020 Aug; 215(2):305-312. PubMed ID: 32551907
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.